Listing & Compliance Notices

Israel Acquisitions Corp received a nasdaq delisting notice notice regarding other (rules 5830).

“January 13, 2026, the Nasdaq Stock Market LLC (“ Nasdaq ”) issued a press release (the “ Nasdaq Press Release ”) pursuant to Nasdaq Listing Rule 5830 and Rule 12d2-2 of the Securities Exchange Act of 1934 (“ Exchange Act ”), as amended, regarding the delisting of the securities of Israel Acquisitions Corp, a Cayman Islands exempted company (the “ Company ”). Pursuant to the Nasdaq Press Release, Nasdaq plans to delist the Company’s (i) Class A ordinary shares, par value $0.0001 per share (the “ Class A Ordinary Shares ”), (ii) units, each consisting of one Class A Ordinary Share and one redeem”

Sadot Group Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 8, 2026, Sadot Group Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5620(a), which requires the Company to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. The Nasdaq letter states that the Company now has 45 calendar days, or until February 22, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq can grant an exception of up to 180 calendar d”

Luminar Technologies, Inc./DE received a nasdaq noncompliance notice notice regarding late filing (rules 5830).

“January 13, 2026 announcing that Nasdaq will file a Form 25 with the Securities and Exchange Commission (the “ SEC ”) to delist and deregister the Company’s Common Stock. The delisting from Nasdaq and deregistration of the Common Stock under Section 12(b) of the Exchange Act will be effective 10 days and 90 days (or such shorter period as the SEC may determine) after the filing of the Form 25, respectively. Trading of the Common Stock on Nasdaq was previously suspended on December 24, 2025 and the stock has not traded on Nasdaq since that time. The Common Stock currently trades on the OTC M”

Telomir Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 8, 2026, the Company received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. The Notice does not result in the immediate delisting of the Company’s securities and has no current effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. Pursuant to the Notice, the Company has”

Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 8, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the Company’s failure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year end of December 31, 2024, it is not in compliance with the continued listing requirements of Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) (the “Nasdaq Annual Meeting Requirement”). Under Nasdaq Listing Rules, the Company has 45 calendar days from January 8, 2026, or until February 23, 2026, to regain compliance or s”

LM FUNDING AMERICA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 7, 2026, LM Funding America, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 6, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rul”

Fat Brands, Inc received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“January 8, 2026, FAT Brands Inc. (the “Company”) received separate written notices (each, a “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, for the period between November 20, 2025 and January 7, 2026: ● With respect to the Company’s Class A Common Stock (Nasdaq: FAT), the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share”

Fat Brands, Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 8, 2026, FAT Brands Inc. (the “Company”) received separate written notices (each, a “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, for the period between November 20, 2025 and January 7, 2026: ● With respect to the Company’s Class A Common Stock (Nasdaq: FAT), the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share”

Advantage Solutions Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“January 7, 2026, Advantage Solutions Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until July 6, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or e”

Onfolio Holdings, Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 6, 2026, Onfolio Holdings Inc. (the “ Company ”) received a written notification (the “ Notice ”) from the Listing Qualifications Staff of The NASDAQ Stock Market (“ NASDAQ ”) stating that the Company is not in compliance with NASDAQ Listing Rule 5550(a)(2) because for the last 33 consecutive business days the closing bid price of the Company’s common stock was below the $1.00 per share minimum required for continued listing on NASDAQ. The Notice has no immediate effect on the listing or trading of the Company’s common stock on the NASDAQ Capital Market. As stated in the Notice, NASDAQ”

TruGolf Holdings, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 5, 2026, TruGolf Holdings, Inc. (the “Company”) received a delinquency notification letter from the Listing Qualifications Staff (“Staff”) of the Nasdaq Stock Market LLC (the “Nasdaq”) due to the Company’s non-compliance with Nasdaq Listing Rule 5620(a) and 5810(c)(2)(G) (the “Listing Rule”) as a result of the Company’s failure to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. The Company per the delinquency notification letter must submit additional information regarding this deficiency to the Staff, in writing no later than Fe”

Brag House Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 6, 2026, Brag House Holdings, Inc. (the “ Company ”) received a deficiency letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the”

Lakeside Holding Ltd received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 7, 2026, Lakeside Holding Limited (the “Company”) received a letter (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, the Company had failed to comply with the minimum bid price of $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”), based on the closing bid price of the Company’s common stock for the previous 30 consecutive business days from November to January 6, 2026. In accordance with”

Capstone Holding Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 7, 2026, Capstone Holding Corp. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, a”

SRx Health Solutions, Inc. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).

“January 6, 2026, SRx Health Solutions, Inc. (the “Company”), received a notice from the NYSE American (“NYSE”), that NYSE has accepted the Company’s plan to regain compliance with Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously disclosed, NYSE notified the Company on October 14, 2025, that the Company had fallen below the NYSE’s continued listing standard requiring a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.”

urban-gro, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 6, 2026, the Company received a determination letter (the “Letter”) from Nasdaq stating that because the Company did not hold an annual meeting of stockholders within twelve months from the Company’s prior fiscal year end as required by Nasdaq Listing Rule 5620(a) (the “Annual Meeting Requirement”), the resulting non-compliance would be an additional basis for delisting the Company’s securities. The Letter notified the Company that the Panel would consider the matter in their decision regarding the Company’s continued listing on the Nasdaq Capital Market, and requested that the Company”

Propanc Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 31, 2025, Propanc Biopharma, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “ Bid Price Requirement ”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bi”

Biofrontera Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 31, 2025, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 34 consecutive business days. The notice has no present impact on the listing or trading of the Company’s securities on The Nasdaq Capital Market. Un”

Inotiv, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 31, 2025, Inotiv, Inc. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. The Notification Letter provides an initial 180 calendar day period, or until June 29, 2026, in”

IMMUNIC, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“al Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. As previously disclosed, on June 27, 2025, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Bid Price Rule”). The Company was given a 180-day grace period, until December 24, 2025, to regain compliance with the rule. The Company had no”

Compass Group Diversified Holdings LLC received a nyse deficiency notice notice regarding other (rules 302).

“January 2, 2026, Compass Diversified Holdings (the “ Trust ” and, together with Compass Group Diversified Holdings LLC, “ CODI ”) received a letter from the New York Stock Exchange (the “ NYSE ”) informing CODI that it is non-compliant with the corporate governance listing standards set forth in Section 302 of the New York Stock Exchange Listed Company Manual (the “ Listed Company Manual ”), which requires issuers to hold an annual meeting during each fiscal year. CODI was unable to hold an annual meeting during its 2025 fiscal year due to the need to complete the restatement of its financial”

Barinthus Biotherapeutics plc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 30, 2025, Barinthus Biotherapeutics plc (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s American Depositary Shares (the “ADS”), each representing one ordinary share of the Company, was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Market. The notice from Nasdaq has no immediate effect on the listing of the ADSs, and t”

Protagenic Therapeutics, Inc.new received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that trading of the Company’s securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company’s securities based on the Company’s failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is gener”

Protagenic Therapeutics, Inc.new received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that trading of the Company’s securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company’s securities based on the Company’s failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is gener”

Bolt Projects Holdings, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“December 31, 2025, Bolt Projects Holdings, Inc. (the “Company”) received written notification from the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that, due to the Company’s having not met the terms of the Panel’s September 30, 2025 decision that the Company demonstrate compliance with the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by December 31, 2025, the Company’s securities will be delisted from Nasdaq, and trading will be suspended at the open of trading on January 5, 2026. The Company has 15 days after the date it re”

Meridian Holdings Inc./NV received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 31, 2025, Golden Matrix Group, Inc. (the “ Company ”, “ we ” or “ us ”) received written notice (the “ Notification Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid pr”

RenovoRx, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 31, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock, par value $0.0001 per share (the “Common Stock”), failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Common Stock for the 32 consecutive business days prior to the date of the notice from Nasdaq. Nasdaq’s notice has no immediate effect on the listing of the Common Stock on Th”

Decoy Therapeutics Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“December 31, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq listing rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share (the “Minimum Bid Price Requirement”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasd”

ELUTIA INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a), 5810(c)(3)(A)).

“November 7, 2025 that it no longer satisfied Nasdaq Listing Rule 5550(a), which requires the Company to maintain a minimum bid price of $1.00 per share (the “ Bid Price Rule ”) for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the notification, or until May 6, 2026, to regain compliance with the Bid Price Rule, which requires that the closing bid price of the Common Stock be at least $1.00 for a minimum of 10 consecutive business days (unless the Staff exercises its discretion”

ELUTIA INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)).

“November 7, 2025 that it no longer satisfied Nasdaq Listing Rule 5550(a), which requires the Company to maintain a minimum bid price of $1.00 per share (the “ Bid Price Rule ”) for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the notification, or until May 6, 2026, to regain compliance with the Bid Price Rule, which requires that the closing bid price of the Common Stock be at least $1.00 for a minimum of 10 consecutive business days (unless the Staff exercises its discretion”

CISO Global, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 30, 2025, we received a letter from the listing qualifications staff (the “Staff”) of Nasdaq providing notification that the bid price of our common stock had closed below $1.00 per share for the previous 33 consecutive business days and our common stock no longer meets the minimum bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days or until June 29, 2026, to regain compliance. To regain compliance, the closing bid price of our common stock must be $1.00 per share or more for”

Functional Brands Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 30, 2025, Functional Brands Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock”

Snail, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 30, 2025, Snail, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for thirty (30) consecutive business days from November 11, 2025 through December 29, 2025, the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”) as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq”

ECD Automotive Design, Inc. received a nasdaq delisting notice notice regarding market value (rules 5810(c)(3)(A)(iv), 5810(c)(3)(A)).

“consecutive business days between November 12, 2025 and December 24, 2025 (the “Bid Price Deficiency”), and, as a result, did not comply with Minimum Bid Rule. Normally, the Company would be provided 180 calendar days to regain compliance with the Minimum Bid Rule, however pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Listing Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period. Accordingly, the December Notice informed the Company that the Bid Price Deficiency se”

ECD Automotive Design, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“consecutive business days between November 12, 2025 and December 24, 2025 (the “Bid Price Deficiency”), and, as a result, did not comply with Minimum Bid Rule. Normally, the Company would be provided 180 calendar days to regain compliance with the Minimum Bid Rule, however pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Listing Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period. Accordingly, the December Notice informed the Company that the Bid Price Deficiency se”

FibroBiologics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 30, 2025, the Company received a second notification indicating that the Staff planned to delist the Company’s securities due to the Company’s continued non-compliance with the Rule as of December 29, 2025, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further suspension or delisting action by the Staff at least pending the outcome of the hearing and the expiration of any extension that may be granted to the Company by the Panel. The Company intend”

FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 1, 2025, FibroBiologics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price for the Company’s shares of common stock had closed below the minimum threshold of $1.00 per share, as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”), for the previous 30 consecutive trading day period. In accordance with Listing Rule 5810(c)(3)(A), the Company was provided with a 180-calendar day period to regain compliance with t”

ProPhase Labs, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 29, 2025, ProPhase Labs, Inc. (the “Company”) received a letter from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company did not regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. As previously disclosed, the Company was provided an initial 180-day compliance period, followed by an additional 180-day compliance period, to regain compliance with the minimum bid price requirement, which expired on December 22, 2025. Nasdaq indicated that trading of the Company’s common stock will be suspended at the o”

Modular Medical, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“December 30, 2025, the Company received written notification from the Listing Qualifications Department of Nasdaq, granting the Company’s request for a 180-day extension to regain compliance with the Bid Price Rule. The Company now has until June 29, 2026 to meet the requirement. If at any time prior to June 29, 2026, the bid price of the Common Stock closes at $1 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule during the additional 180-day extension, N”

Laser Photonics Corp received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“December 30, 2025, the registrant (“Laser Photonics” or the “Company”) received a letter of compliance from Nasdaq stating that based on the Company having filed on December 23, 2025, its Form 10-Q for the period ended September 30, 2025, the Staff has determined that Laser Photonics complies with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the “Rule”) and that the matter of non-compliance with the Rule addressed in its November 20, 2025, notice to the Company was now closed. A copy of the press release announcing the compliance notice is attached”

Triller Group Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“December 26, 2025, the Company received notice from the Panel stating that the Panel had determined to delist the Company’s securities from Nasdaq and that trading in the Company’s securities on Nasdaq would be suspended effective with the open of the market on December 30, 2025. The Company plans to seek the Panel’s reconsideration of its decision in accordance with the Nasdaq Listing Rules and to otherwise timely appeal the Panel’s decision to the Nasdaq Listing and Hearing Review Council (the “Listing Council”). There can be no assurance that the Company will succeed in its efforts to obtai”

IMMERSION CORP received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“m Nasdaq notifying the Company that it did not timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 (the “Q1 Form 10-Q”). The Q1 Form 10-Q, the Q2 Form 10-Q and the Form 10-K are required to be filed for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5250(c)(1). Under Nasdaq rules, the Company has to submit to Nasdaq by no later than January 7, 2026 an update to its original plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) which was previously submitted to Nasdaq on October 20, 2025. As previously reported on the Company’s Notificat”

DYADIC INTERNATIONAL INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 19, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum bid price of at least $1 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5”

NOODLES & Co received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5505(b)).

“December 23, 2025 (the “Delisting Determination Letter”). The Delisting Determination Letter states that unless the Company requests a hearing before a Nasdaq Hearings Panel (the “Panel”) by December 30, 2025, the Company’s securities would be subject to suspension/delisting. Accordingly, the Company intends to request a hearing before the Panel on or before December 30, 2025. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In connection with the”

Vivakor, Inc. received a nasdaq deficiency notice notice regarding other (rules 5635(d)).

“December 11, 2025, the Staff notified the Company that it had failed to comply with Nasdaq’s shareholder approval requirements set forth in Listing Rule 5635(d), which requires prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) and requested that the Company submit a compliance plan no later than January 26, 2026. However, the Letter advised that pursuant to Listing Rule 5810(c)(2), this deficiency serves as a se”

Vivakor, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).

“December 19, 2025, the Company received a notification letter (the “Letter”) from the Staff that as of December 19, 2025, the Common Stock had a closing bid price of $0.10 or less for ten consecutive trading days and accordingly, the Company was subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”) and not eligible for the remainder of the Second Grace Period. The Letter advised that, since the Company did not regain compliance with the Minimum Bid Price Requirement within the Second Grace Period, the Common Stock will be delisted from The”

Silo Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 27, 2025, the Company received a notification (the “Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Company init”

UWM Holdings Corp received a nyse delisting notice notice regarding other (rules 802.01D).

“December 19, 2025, UWM Holdings Corporation (the “Company”) received notice from the New York Stock Exchange (the “NYSE”) that the NYSE has determined to (i) commence proceedings to delist the Company’s warrants (the “Warrants”) and (ii) immediately suspend trading in the Warrants due to “abnormally low selling price” levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. Each Warrant is presently exercisable for one share of the Company’s Class A common stock (the “Common Stock’) at an exercise price per share of $11.50 and are set to expire January 21, 2026, ticker symbol “UW”

Fly-E Group, Inc. received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“December 18, 2025, and received a letter from Nasdaq informing the Company that it has regained compliance with the Rule as a result of the Company’s filing of its Form 10-Q (the “ Letter ”). As the Company has regained compliance, the receipt of the Letter confirmed that the matter was now closed. 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fly-E Group, Inc. Date: December 29, 2025 By: /s/ Zhou Ou Name: Zhou Ou Title: Chief Executive Offic”

Teads Holding Co. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 22, 2025, Teads Holding Co. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price of the Company’s common stock has been below the required minimum of $1.00 per share (the “Minimum Bid Price Requirement”) for 30 consecutive business days. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which continues to trade on The Nasdaq Global Select Market u”